Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | GRIA4 | P48058 | 9/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | CDC42 | P60953 | 1/20 | 0.49 |
| ▸ | RAC1 | P63000 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13256275 | 0.89 | GRIA4 (0.64) | ABCB11GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL13255828 | 0.89 | GRIA4 (0.64) | ABCB11GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL5878488 | 0.88 | GRIA4 (0.63) | GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL6759349 | 0.84 | GRIA4 (0.49) | ABCB11GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL6573578 | 0.83 | GRIA4 (0.50) | ABCB11GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL13255822 | 0.82 | GRIA4 (0.58) | GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL6575871 | 0.82 | ABCB11 (0.54) | ABCB11GRIA4PTGS2AKR1C3AKR1C2 | |
| SCHEMBL6762646 | 0.82 | GRIA4 (0.52) | ABCB11GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL6572001 | 0.81 | GRIA4 (0.55) | GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL6762959 | 0.81 | KDM4E (0.47) | GRIA4GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | DAVISON JOSHUA ZWICK (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1409452-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002098846-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, GRIA1 | ABCB11 666/4885GRIA4 9/4885GRIA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.